Codiak Biosciences Inc. closed a $76.5 million series C, extending its runway in a big way following a combined series A/B that hit $92 million. Initial investors, including Arch Venture Partners, Flagship Pioneering, Fidelity Management and Research Co., the Alaska Permanent Fund and Alexandria Venture Investments, participated in the C round, joined by new investors that included Qatar Investment Authority, Boxer Capital of the Tavistock Group, Sirona Capital, Ecor1 Capital and Casdin Capital.